Brief: Can-Fite Developing Topical Piclidenoson Psoriasis Treatment That Shows Efficacy In A Preclinical Model
05/04/2022 12:27
April 5 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN-FITE IS DEVELOPING A TOPICAL PICLIDENOSON PSORIASIS
TREATMENT THAT SHOWS EFFICACY IN A PRECLINICAL MODEL: POTENTIAL
COMPLEMENTARY PRODUCT TO ITS PHASE III ORAL PSORIASIS DRUG
* CAN FITE BIOPHARMA LTD- TOPLINE RESULTS FROM PHASE III
ORAL
PICLIDENOSON STUDY EXPECTED Q2 2022
Source text for Eikon: ID:nBw50pDLMa
Further company coverage: CANF.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage